{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361699994154033408.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1128/aac.01440-06"}},{"identifier":{"@type":"URI","@value":"https://journals.asm.org/doi/pdf/10.1128/AAC.01440-06"}}],"dc:title":[{"@value":"In Vitro Activity of 2,4-Diamino-6-[2-(Phosphonomethoxy)Ethoxy]-Pyrimidine against Multidrug-Resistant Hepatitis B Virus Mutants"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>ABSTRACT</jats:title><jats:p>The susceptibilities of drug-resistant hepatitis B virus (HBV) mutants to lamivudine, adefovir, tenofovir, entecavir, and 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine (PMEO-DAPym), a novel acyclic pyrimidine analogue, were assessed in vitro. Most drug-resistant mutants, including multidrug-resistant strains, remained sensitive to tenofovir and PMEO-DAPym. Therefore, the latter molecule deserves further evaluation for the treatment of HBV infection.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381699994154033410","@type":"Researcher","foaf:name":[{"@value":"M. N. Brunelle"}],"jpcoar:affiliationName":[{"@value":"INSERM, U871, 151 Cours Albert Thomas, 69003 Lyon, France"},{"@value":"Université Lyon 1, 69008 Lyon, France"},{"@value":"IFR62 Lyon Est, Faculté de Médecine Laennec, 69008 Lyon, France"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994154033412","@type":"Researcher","foaf:name":[{"@value":"J. Lucifora"}],"jpcoar:affiliationName":[{"@value":"INSERM, U871, 151 Cours Albert Thomas, 69003 Lyon, France"},{"@value":"Université Lyon 1, 69008 Lyon, France"},{"@value":"IFR62 Lyon Est, Faculté de Médecine Laennec, 69008 Lyon, France"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994154033408","@type":"Researcher","foaf:name":[{"@value":"J. Neyts"}],"jpcoar:affiliationName":[{"@value":"Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994154033411","@type":"Researcher","foaf:name":[{"@value":"S. Villet"}],"jpcoar:affiliationName":[{"@value":"INSERM, U871, 151 Cours Albert Thomas, 69003 Lyon, France"},{"@value":"Université Lyon 1, 69008 Lyon, France"},{"@value":"IFR62 Lyon Est, Faculté de Médecine Laennec, 69008 Lyon, France"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994154033414","@type":"Researcher","foaf:name":[{"@value":"A. Holy"}],"jpcoar:affiliationName":[{"@value":"Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994154033413","@type":"Researcher","foaf:name":[{"@value":"C. Trepo"}],"jpcoar:affiliationName":[{"@value":"INSERM, U871, 151 Cours Albert Thomas, 69003 Lyon, France"},{"@value":"Université Lyon 1, 69008 Lyon, France"},{"@value":"IFR62 Lyon Est, Faculté de Médecine Laennec, 69008 Lyon, France"},{"@value":"Hospices Civils de Lyon, Hôtel Dieu Hospital, 69002 Lyon, France"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994154033409","@type":"Researcher","foaf:name":[{"@value":"F. Zoulim"}],"jpcoar:affiliationName":[{"@value":"INSERM, U871, 151 Cours Albert Thomas, 69003 Lyon, France"},{"@value":"Université Lyon 1, 69008 Lyon, France"},{"@value":"IFR62 Lyon Est, Faculté de Médecine Laennec, 69008 Lyon, France"},{"@value":"Hospices Civils de Lyon, Hôtel Dieu Hospital, 69002 Lyon, France"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00664804"},{"@type":"EISSN","@value":"10986596"}],"prism:publicationName":[{"@value":"Antimicrobial Agents and Chemotherapy"}],"dc:publisher":[{"@value":"American Society for Microbiology"}],"prism:publicationDate":"2007-06","prism:volume":"51","prism:number":"6","prism:startingPage":"2240","prism:endingPage":"2243"},"reviewed":"false","dc:rights":["https://journals.asm.org/non-commercial-tdm-license"],"url":[{"@id":"https://journals.asm.org/doi/pdf/10.1128/AAC.01440-06"}],"createdAt":"2007-03-20","modifiedAt":"2023-05-11","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360285707257585408","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Characterization of novel entecavir resistance mutations"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567180081466752","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Resistance mutations of hepatitis B virus in entecavir‐refractory patients"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1128/aac.01440-06"},{"@type":"CROSSREF","@value":"10.1002/hep4.1022_references_DOI_LwpyqXn8g4i3gukgMGnsfRmBrCW"},{"@type":"CROSSREF","@value":"10.1016/j.jhep.2015.03.020_references_DOI_LwpyqXn8g4i3gukgMGnsfRmBrCW"}]}